A recent report published in the American Journal of Case Reports describes a rare case of drug reaction with eosinophilia and systemic symptoms (DRESS)-induced agranulocytosis in a patient treated with the beta-lactam antibiotic oxacillin.
A recent study published in the New England Journal of Medicine assessed the risk of new-onset psychosis among adolescents and young adults with attention deficit hyperactivity disorder (ADHD) initiated on various stimulant medications.
Results from 3 studies evaluating the interaction between Addyi (flibanserin; Sprout), a treatment for hypoactive sexual desire disorder in premenopausal women, and alcohol have been submitted to the FDA for review for inclusion in the product labeling.
Biogen and Eisai have made the decision to discontinue two phase 3 trials evaluating aducanumab for the treatment of mild cognitive impairment due to Alzheimer disease (AD) and mild AD dementia.
The Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab; Genentech), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer.
Results from the phase 4 AUGUSTUS trial, evaluating apixaban vs vitamin K antagonists in patients with nonvalvular atrial fibrillation and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention.
Treatment with icosapent ethyl was associated with a substantial reduction in the risk of first, subsequent, and total ischemic events when compared with placebo in statin-treated patients with established cardiovascular (CV) disease or diabetes with other CV risk factors.
The Food and Drug Administration has expanded the approval of Avycaz (ceftazidime and avibactam) to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections, used in combination with metronidazole, and for complicated urinary tract infections.
Elderberry supplementation may reduce the duration and severity of upper respiratory symptoms, according to a meta-analysis published in the journal Complementary Therapies in Medicine.
The Food and Drug Administration (FDA) has granted Fast Track designation to nalmefene HCl injection (Purdue Pharma) for the emergency treatment of known or suspected opioid overdoses.
